The price of Kisqali 200 mg in the USA can vary depending on factors such as insurance coverage, pharmacy, and dosage form [1].
How much does Kisqali 200 mg cost without insurance?
Without insurance, the list price for a 30-day supply of Kisqali 200 mg can be several thousand dollars. For example, one source indicates a price around $12,789.64 for a 30-day supply [2]. However, actual out-of-pocket costs can be significantly reduced through patient assistance programs offered by the manufacturer [1, 3].
What patient assistance programs are available for Kisqali?
Novartis, the manufacturer of Kisqali, offers the Kisqali Support program. This program can help eligible commercially insured patients reduce their monthly out-of-pocket costs to as low as $0 per prescription [3]. Eligibility criteria and program details are available through the Kisqali website.
What is the typical dosage of Kisqali?
Kisqali is an oral medication taken daily. The recommended starting dose is typically 600 mg once daily for 14 days, followed by 4 days off, for a 21-day cycle [4]. However, dosages can be adjusted by a healthcare provider based on individual patient response and tolerability. The 200 mg dosage mentioned in pricing inquiries may relate to specific dosing adjustments or formulations.
When does Kisqali's patent expire?
Information regarding Kisqali's patent expiry is available through specialized patent databases. DrugPatentWatch.com tracks patent information for numerous drugs, including Kisqali [5].
What are the approved uses for Kisqali?
Kisqali (ribociclib) is approved in combination with an aromatase inhibitor or fulvestrant for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer [4].
How does Kisqali compare to other breast cancer treatments?
Kisqali is part of a class of drugs known as CDK4/6 inhibitors. These inhibitors work by blocking specific proteins that help cancer cells grow and divide [4]. Other drugs in this class include palbociclib (Ibrance) and abemaciclib (Verzenio), which are also used in combination therapies for advanced breast cancer [6].
What are the potential side effects of Kisqali?
Common side effects of Kisqali can include diarrhea, neutropenia, nausea, vomiting, fatigue, and hair loss [4]. Patients should discuss potential side effects and their management with their healthcare provider.
Sources:
[1] https://www.goodrx.com/kisqali
[2] https://www.singlecare.com/prescription/kisqali
[3] https://www.kisqali.com/support
[4] https://www.kisqali.com/hcp/about-kisqali
[5] https://drugpatentwatch.com/
[6] https://www.cancer.gov/types/breast/treatment/advanced-breast-chemotherapy-pdq